Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution

DRUG3 trials

Sponsors

Aerie Pharmaceuticals, University Hospital Dubrava, Mayo Clinic

Conditions

GlaucomaOcular HypertensionOpen Angle GlaucomaPseudophakic Bullous Keratopathy

Phase 4

Rocklatan® Evaluation

CompletedNCT05283395

Aerie PharmaceuticalsGlaucoma

Start: 2022-03-28End: 2023-03-22Updated: 2024-04-03

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

RecruitingNCT07325240

Mayo ClinicOcular Hypertension, Open Angle Glaucoma

Start: 2025-11-21End: 2027-10-01Target: 30Updated: 2026-05-01

Unknown Phase

The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)

Enrolling by invitationNCT06960629

University Hospital DubravaGlaucoma, Pseudophakic Bullous Keratopathy

Start: 2025-04-01End: 2026-10-01Target: 50Updated: 2025-05-20